论文部分内容阅读
Hepatocellular carcinoma(HCC)is the third most common cause of cancer death worldwide(1).Most patients present with intermediate or advanced disease that is not amenable to curative treatment,and the median survival in this group is 6-8 months(2).Several studies and welldesigned randomized trials have shown a positive effect
The patients with intermediate or advanced disease that is not amenable to curative treatment, and the median survival in this group are 6-8 months (2) .Several studies and welldesigned randomized trials have shown a positive effect